Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug combo aims to tackle tough lymphoma

NCT ID NCT06810778

Recruiting now Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial investigates whether combining two FDA-approved drugs, duvelisib and venetoclax, can safely and effectively treat peripheral T-cell lymphoma that has returned or stopped responding to prior therapies. The study enrolls adults who have tried at least two previous treatments. Researchers will first find the safest dose, then measure how well the combination shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
duvelisib and venetoclax
What this could lead to
If successful, this combination could offer a new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma who have limited choices.
What could go wrong
This is an early-phase trial with only 12 participants, so results may not apply broadly. The combination is experimental and may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leukemia mature T-cell and NK-cell non-Hodgkin lymphoma primary cutaneous T-cell non-Hodgkin lymphoma Recurrence T-cell prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T-CELL LYMPHOMA REFRACTORY T CELL PROLYMPHOCYTIC LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • David Geffen School of Medicine at the University of California at Los Angeles

    RECRUITING

    Los Angeles, California, 90095-1406, United States

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.